NCT04134559 2026-02-24
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
Dana-Farber Cancer Institute
Phase 2 Recruiting
Clinical Trials
24 trialsNCT07412054 2026-02-17
BLP-HCC
Fudan University
Phase 2 Not yet recruiting
NCT03519997 2026-02-11
A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma
University of Texas Southwestern Medical Center
Phase 2 Active not recruiting
NCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT04798781 2025-12-11
Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma
Cedars-Sinai Medical Center
Phase 2 Completed
NCT07157969 2025-12-01
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT04828486 2025-11-18
Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer
Mayo Clinic
Phase 2 Completed
NCT05256381 2025-11-17
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Sotio Biotech Inc.
Phase 2 Terminated
NCT07223424 2025-11-10
PSI-Immune
University of Pittsburgh
Phase 2 Recruiting
NCT05104567 2025-09-24
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Sanofi
Phase 2 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03316872 2025-07-25
Study of Pembrolizumab and Radiotherapy in Liver Cancer
University Health Network, Toronto
Phase 2 Terminated
NCT05101629 2025-07-23
Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT02940496 2025-07-15
Pembrolizumab (MK-3475) in Hepatocellular Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04696055 2025-05-13
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
Bayer
Phase 2 Completed
NCT04114136 2025-02-10
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
University of Pittsburgh
Phase 2 Recruiting
NCT05185739 2024-12-06
PRIMER-1
University College, London
Phase 2 Recruiting
NCT02702414 2024-09-04
KEYNOTE-224
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04770207 2024-08-21
Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT03753659 2024-07-22
IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT06492408 2024-07-09
Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT06389422 2024-04-29
Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT03836352 2022-03-31
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase 2 Active not recruiting
NCT03337841 2017-11-09
Pembrolizumab as Neoadjuvant Treatment in HCC
Kindai University
Phase 2 Unknown